TCT-37: Are Adverse Events Following Primary PCI for STEMI More Frequent at US Sites than Sites Outside the US (OUS)? Three-Year Analysis from the HORIZONS-AMI Trial  by unknown
TUESDAY, NOVEMBER 8, 2011, 10:15 AM - 12:25 PM
lesion failure and TLR, were adjudicated per ARC definition by an independent
Clinical Events Committee. Demographic, clinical, and procedural variables were
assessed using multivariable, stepwise, Cox regression analysis with independent
variables entered into the model at the 0.05 significance level. A time-dependent
covariate was used to assess the association between dual antiplatelet therapy (DAPT)
interruption and subsequent ST occurrence.
Results: There are two enrollment phases in this study with a total of 8061 patients,
including ~ 61% off-label patients. The 1-year clinical outcomes and their independent
predictors are shown in the table. About 80% of patients were treated with DAPT at 1
year.
1 Target lesion failure = cardiac death, MI (per ARC) attributed to target vessel and
clinically-indicated TLR.
Conclusion: In this large, complex, real-world population, XIENCE V demonstrated
low event rates at 1 year. In addition to clinical and lesion related variables, the
multivariate analysis revealed that premature DAPT interruption within 30 days was
an independent predictor of ST with the highest hazard ratio. However, DAPT
interruption after 30 days was not associated with subsequent ST.
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Background: RESOLUTE first-in-man (FIM) was the first study to evaluate the
Resolute zotarolimus-eluting stent (R-ZES, Medtronic, Inc, Santa Rosa, CA) in 130
patients treated for a single de novo lesion ≥ 14 mm and ≤ 27 mm in length, with a
reference vessel diameter of ≥ 2.5 mm and ≤ 3.5 mm. The R-ZES comprises a cobalt-
alloy, thin strut, metal stent; and a biocompatible polymer that allows prolonged drug
elution; with 85% eluted within the first 60 days, and the remaining exhausted by 180
days. The RESOLUTE FIM study is part of the global RESOLUTE Clinical Trial
Program, which comprises at least 5 trials specifically designed with consistent
endpoint definitions; standardized data collection, analysis and adjudication methods
to promote poolability. To date, the R-ZES has been studied in over 5000 patients; at
over 200 investigational sites worldwide.
Methods: Patients were enrolled from December 6, 2005 through June 9, 2006 at 12
centers in Australia and New Zealand. The primary endpoint was in-stent late loss at
9 months. The final 5-year follow-up outcomes will be reported.
Results: Baseline patient clinical characteristics include hyperlipidemia (94.6%),
hypertension (67.7%), prior MI (45.7%), unstable angina (29.7%), and diabetes
(17.7%). Of 131 lesions treated (2 lesions in 1 patient), mean length was 15.49±6.23
mm, 82% were B2/C, and 46.2% of patients had multivessel disease. At 4 years, the
cumulative incidence of TLR was 2.3%, TVF was 10.1%, MACE was 14.0%; without
any ARC definite and probable ST events at 4 years follow-up. At 4 years, 33.9% of
patients were still on dual antiplatelet therapy.
Conclusion: The R-ZES has shown long-term effectiveness and safety in a relatively
simple patient cohort through 4-year follow-up with a TLR rate of 2.3% and an ARC
definite and probable ST rate of 0.0%. We plan to report the final, 5-year clinical
outcomes in November, 2011 at the annual meeting of Transcatheter Cardiovascular
Therapeutics.
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Background: The XIENCE V everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) demonstrated superior efficacy and long term safety in the SPIRIT clinical
trials series. The next generation XIENCE PRIME EES includes 2.25 mm diameters
and 33 and 38 mm lengths to treat small vessels and long lesions (LL). The SPIRIT
PRIME trial aimed to show clinical equivalence of the XIENCE PRIME and XIENCE
V stents.
Methods: SPIRIT PRIME, a prospective, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME core sizes and LL (33 and 38 mm) stents.
The primary endpoint is 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data
according to FDA requirements. The Core Size Registry (CSR) analyzed 401 patients
and the Long Lesion Registry (LLR) 104 patients. Treatment of up to 2 de novo lesions
in different epicardial vessels was allowed. Data were fully monitored and all endpoint
events adjudicated by an independent committee.
Results: There were 447 CSR and 124 LLR lesions treated and a total of 530 XIENCE
PRIME and 105 XIENCE PRIME LL stents implanted. Clinical device success rates
were 98.2% (CSR) and 97.6% (LLR). Female and diabetic subjects were 29.7% and
34.9%, respectively in the CSR and 37.5% and 35.6%, respectively in the LLR. In both
arms, the primary endpoint was met by all analyses. The Table shows 1-year outcomes.
Conclusion: The SPIRIT PRIME study demonstrated 1-year safety and efficacy of the
new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in core size
and LL cohorts, suggesting clinical equivalence of the XIENCE PRIME stent to
XIENCE V.
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